UTI Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV as on 20-12-2024
₹ 321.02
▲0.4%
1D
Inception Returns
17.4%
/yr
About UTI Healthcare Fund Direct Growth
UTI Healthcare Fund Direct Growth is an equity fund. This fund was started on 1 January, 2013. The fund is managed by . The fund could potentially beat inflation in the long-run.
Key Parameters
- UTI Healthcare Fund Direct Growth has ₹1203 Cr worth of assets under management (AUM) as on Nov 2024 and is less than category average.
- The fund has an expense ratio 1.3.
Returns
UTI Healthcare Fund Direct Growth has given a CAGR return of 17.38% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 45.92%, 23.58% and 29.13% respectively.
Holdings
UTI Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Ajanta Pharma Ltd, Dr Reddy's Laboratories Ltd, Glenmark Pharmaceuticals Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 15%For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefitDividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.
Investment objective of UTI Healthcare Fund Direct Growth
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 500.00. UTI Healthcare Fund Direct Growth has no lock in period.
Historical NAV & Returns
Annualised
▲
▼
281 people have invested ₹ 63.6L in UTI Healthcare Fund Direct Growth in the last three months
INDmoney Rank for UTI Healthcare Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
Beats FD returns for both 3Y & 5Y duration
No bad points found for this fund.
UTI Healthcare Fund Direct Growth Overview
| Expense ratio | 1.25% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹1203 Cr |
| Inception Date | 1 January, 2013 |
| Min Lumpsum/SIP | ₹5000/₹500 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 24.75% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (20-Dec-24)
Fund Distribution
as on (30-Nov-24)
Small cap
36.4%
Large cap
32.1%
Mid cap
26.3%
Sector Allocation
Health
98.1%
Basic Materials
1.5%
Financial Services
0.4%
All changes are between Sep'24 and Nov'24
- This fund’s returns stands at 0.95% whereas the fund’s underlying benchmark Nifty 500 returns stands at -0.60% as on Nov'24
- This fund outperformed Nifty 500 by 1.55% in Nov'24
- AUM of the fund stands at 1.2K Cr as of Nov'24
- AUM increased by 16.2 Cr between Nov'24 and Oct'24
Top Stocks bought last month
Alkem Laboratories Ltd's allocation increased from 2.07% to 2.96%
Glenmark Pharmaceuticals Ltd's allocation increased from 3.57% to 3.93%
Krishna Institute of Medical Sciences Ltd's allocation increased from 2.84% to 3.09%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 11.29 % to 10.73 %
Cipla Ltd's allocation decreased from 5.89 % to 5.75 %
Ajanta Pharma Ltd's allocation decreased from 5.38 % to 4.85 %
Large Cap allocation has gone down from 32.8% to 32.1%
Small Cap allocation has gone up from 35.6% to 36.4%
Mid Cap allocation has gone down from 26.6% to 26.3%
Cash allocation has gone up from 1.4% to 2.1%
Debt allocation has gone down from 0.1% to 0%
Top 3 Sectors in November were Health, Government & Basic Materials
Nov'24
Health
98%
Basic Materials
1%
Oct'24
Health
97%
Government
7%
Basic Materials
2%
See all
Top Growth Drivers | 1M Return |
|---|---|
 Marksans Pharma Ltd | 4.8% |
 Krishna Institute of Medical Sciences Ltd | 2.7% |
 Vijaya Diagnostic Centre Ltd | 0.2% |
Loading...
We are taking more time than usual
Fund House
UTI Asset Management Co Ltd
Total Schemes
Total AUM
₹2.36L Cr
as on 29-Nov-2024
Address
PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051
Phone
+912266786666
Website
service@uti.co.in
Mutual Fund Insights
In the last 3 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 26.95% return, outperforming this fund by 3.37% per annum.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.25% which is lower than the category average expense ratio of 1.39%.
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 53.39% return, outperforming this fund by 7.47%.
In the last 5 years, DSP Healthcare Fund Direct Growth has given 32.82% return, outperforming this fund by 3.69% per annum.
Over the last 1 year, this fund has decreased expense ratio by 10.7% moving from 1.40 to 1.25.
Over the last 6 months, this fund has experienced a 28.2% growth in AUM moving from 938.43 Cr to 1.20K Cr.
UTI Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 17.38% since inception which is less than its category average return of 24.91%
Fund Allocations
This fund has an allocation of 97.88% in Equity, 0% in Debt and 2.12% in Cash related instruments
AUM size ₹1203 Cr
This fund has AUM of ₹1203 Cr which is less than its category average of ₹ 1857 Cr
Expense Ratio 1.25%
This fund has an expense ratio of 1.25% which is more than its category average expense ratio of 1.22%
Frequently Asked Questions for UTI Healthcare Fund Direct Growth
The current NAV of UTI Healthcare Fund Direct Growth is ₹321.02 as on 20-Dec-2024.
Existing (Absolute + CAGR) as on 20-Dec-2024.
UTI Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 4.09% | 4.09% |
6 Month Returns | 23.4% | 23.4% |
1 Year Returns | 45.92% | 45.92% |
3 Years Returns | 88.73% | 23.58% |
5 Years Returns | 259% | 29.13% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.25% as on November 2024
₹1203 Cr as on November 2024
Sun Pharmaceuticals Industries Ltd(10.73%), Cipla Ltd(5.75%), Ajanta Pharma Ltd(4.85%), Dr Reddy's Laboratories Ltd(4.7%), Glenmark Pharmaceuticals Ltd(3.93%) as on November 2024
Health(96.07%), Basic Materials(1.42%), Financial Services(0.39%) as on November 2024
The alpha ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
UTI Healthcare Fund Direct Growth | 1.52 | 1.84 | 2.6 |
As on November 2024
The alpha for UTI Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
UTI Healthcare Fund Direct Growth | 0.99 | 0.96 | 0.93 |
As on November 2024
The Beta for UTI Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
UTI Healthcare Fund Direct Growth | 2.51 | 0.98 | 1.18 |
As on November 2024
The sharpe ratio for UTI Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
UTI Healthcare Fund Direct Growth | 12.94 | 15.68 | 18.7 |
As on November 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.87 as on November 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.49 as on November 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
The Exit load of UTI Healthcare Fund Direct Growth is 1%